NASDAQ:ENLV - Nasdaq - IL0011319527 - Common Stock - Currency: USD
NASDAQ:ENLV (5/23/2025, 9:30:12 PM)
0.975
+0.01 (+1.34%)
The current stock price of ENLV is 0.975 USD. In the past month the price decreased by -0.96%. In the past year, price decreased by -30.36%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 17.84 | 324.18B | ||
AMGN | AMGEN INC | 13.09 | 146.06B | ||
GILD | GILEAD SCIENCES INC | 13.87 | 133.68B | ||
VRTX | VERTEX PHARMACEUTICALS INC | N/A | 112.09B | ||
REGN | REGENERON PHARMACEUTICALS | 13.28 | 63.52B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 37.72B | ||
ARGX | ARGENX SE - ADR | 100.1 | 35.88B | ||
ONC | BEIGENE LTD-ADR | 6 | 26.02B | ||
BNTX | BIONTECH SE-ADR | N/A | 23.72B | ||
NTRA | NATERA INC | N/A | 20.84B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 19.20B | ||
BIIB | BIOGEN INC | 7.95 | 18.43B |
Enlivex Therapeutics Ltd. engages in the development of macrophage reprogramming immunotherapy products. AllocetraTM is a therapy designed to reprogram macrophages into their homeostatic state. Diseases such as solid cancers, sepsis, COVID-19 and many others reprogram macrophages out of their homeostatic state. These non-homeostatic macrophages contribute significantly to the severity of the respective diseases. By restoring macrophage homeostasis, AllocetraTM has the potential to provide immunotherapeutic mechanism of action for life-threatening clinical indications that are defined as unmet medical needs, as a stand-alone therapy or in combination with therapeutic agents.
ENLIVEX THERAPEUTICS LTD
14 Einstein St.
Ness Ziona 7403618 IL
CEO: Oren Hershkovitz
Employees: 71
Phone: 97286623301
The current stock price of ENLV is 0.975 USD. The price increased by 1.34% in the last trading session.
The exchange symbol of ENLIVEX THERAPEUTICS LTD is ENLV and it is listed on the Nasdaq exchange.
ENLV stock is listed on the Nasdaq exchange.
8 analysts have analysed ENLV and the average price target is 10.2 USD. This implies a price increase of 946.15% is expected in the next year compared to the current price of 0.975. Check the ENLIVEX THERAPEUTICS LTD stock analysts ratings, price target forecast and up-and down grades for more detailed information.
ENLIVEX THERAPEUTICS LTD (ENLV) has a market capitalization of 21.44M USD. This makes ENLV a Nano Cap stock.
ENLIVEX THERAPEUTICS LTD (ENLV) currently has 71 employees.
ENLIVEX THERAPEUTICS LTD (ENLV) has a support level at 0.85 and a resistance level at 1.04. Check the full technical report for a detailed analysis of ENLV support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
ENLV does not pay a dividend.
ENLIVEX THERAPEUTICS LTD (ENLV) will report earnings on 2025-05-23.
ENLIVEX THERAPEUTICS LTD (ENLV) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.73).
The outstanding short interest for ENLIVEX THERAPEUTICS LTD (ENLV) is 0.71% of its float. Check the ownership tab for more information on the ENLV short interest.
ChartMill assigns a fundamental rating of 2 / 10 to ENLV. No worries on liquidiy or solvency for ENLV as it has an excellent financial health rating, but there are worries on the profitability.
Over the last trailing twelve months ENLV reported a non-GAAP Earnings per Share(EPS) of -0.73. The EPS increased by 53.21% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -63.54% | ||
ROE | -71.21% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 83% to ENLV. The Buy consensus is the average rating of analysts ratings from 8 analysts.